Medios More than the Doctor ordered Healthcare | Specialty Pharma BUY | TP EUR65
We initiate Medios with BUY rating and a EUR 65 price target as we believe Medios can go on to consolidate its market leading position in the specialty pharmaceutical sector in Germany.With a strong track record of growth and excellent relations with rest of the industry we believe Medios can stand to capitalise on the fast-growing specialty pharma market. We see
significant upside in the share price in the light of recent acquisitions Medios’ has executed in the past 18 months with positive long-term growth and strong synergy potential.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.